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Female sex hormones mediate the allergic lung
reaction by regulating the release of
inflammatory mediators and the expression
of lung E-selectin in rats
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Adriana Lino dos Santos Franco1, Helori Vanni Domingos1, Sonia Maria Oliani4, Ricardo Martins Oliveira-Filho1,
Bernardo Boris Vargaftig1, Wothan Tavares-de-Lima1*
Abstract
Background: Fluctuations of estradiol and progesterone levels caused by the menstrual cycle worsen asthma
symptoms. Conflicting data are reported in literature regarding pro and anti-inflammatory properties of estradiol
and progesterone.
Methods: Female Wistar rats were ovalbumin (OVA) sensitized 1 day after resection of the ovaries (OVx). Control
group consisted of sensitized-rats with intact ovaries (Sham-OVx). Allergic challenge was performed by aerosol
(OVA 1%, 15 min) two weeks later. Twenty four hours after challenge, BAL, bone marrow and total blood cells
were counted. Lung tissues were used as explants, for expontaneous cytokine secretion in vitro or for
immunostaining of E-selectin.
Results: We observed an exacerbated cell recruitment into the lungs of OVx rats, reduced blood leukocytes
counting and increased the number of bone marrow cells. Estradiol-treated OVx allergic rats reduced, and those
treated with progesterone increased, respectively, the number of cells in the BAL and bone marrow. Lungs of OVx
allergic rats significantly increased the E-selectin expression, an effect prevented by estradiol but not by
progesterone treatment. Systemically, estradiol treatment increased the number of peripheral blood leukocytes in
OVx allergic rats when compared to non treated-OVx allergic rats. Cultured-BAL cells of OVx allergic rats released
elevated amounts of LTB4 and nitrites while bone marrow cells increased the release of TNF-a and nitrites.
Estradiol treatment of OVx allergic rats was associated with a decreased release of TNF-a, IL-10, LTB4 and nitrites by
bone marrow cells incubates. In contrast, estradiol caused an increase in IL-10 and NO release by cultured-BAL
cells. Progesterone significantly increased TNF- a by cultured BAL cells and bone marrow cells.
Conclusions: Data presented here suggest that upon hormonal oscillations the immune sensitization might trigger
an allergic lung inflammation whose phenotype is under control of estradiol. Our data could contribute to the
understanding of the protective role of estradiol in some cases of asthma symptoms in fertile ans post-menopausal
women clinically observed.
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Introduction
Compelling evidence indicates that female sex hormones
play a role not only in healthy airway function but also
during inflammation. In the context of airway dysfunc-
tion, it is noteworthy that oscillations of sex hormones
caused by the menstrual cycle might be linked to
asthma deterioration [1,2]. Premenstrual worsening of
asthma was described more than 70 years ago [3], with
nearly half of asthmatic women exhibiting increased
respiratory discomfort during the menstrual period [4].
In addition, there is an exacerbation of asthma symp-
toms [5] and a decline in lung function [6] at the luteal
phase of the cycle, when estradiol levels decrease. Con-
versely, the frequency and severity of asthma deteriora-
tion reduces when serum levels of estradiol are high, as
observed after exogenous estradiol, oral contraceptives
usage and during ovulation [7]. In fact, forced expiratory
volume and vital capacity are higher during early luteal
phase, when estradiol and progesterone levels are high
[8]. Overall, these data reinforce the inverse correlation
between female sex hormone levels and deterioration of
asthma symptoms. Of interest is the data reporting that
menstrual cycle, contraceptive usage and hormonal
replacement therapy account for asthma deterioration in
women [9-14], a fact whose mechanisms are yet unclear.
Asthma is a Th2-lymphocytes mediated disease and
interestingly the fluctuations of circulating female sex
hormones during the menstrual cycle lead to a signifi-
cant increase of cytokines associated to a Th2-type of
response [15]. Accordingly, IL-4 production by CD4+ T
cells is affected by cyclical variations of circulating estra-
diol levels [16,17]. Yet, lymphocytes of asthmatic women
did not express normal b2 adrenoceptors, a fact that
might be related to increased bronchial responsiveness
[18].
We have recently demonstrated that OVA sensitiza-
tion 7 days after ovariectomy widely reduces IL-5 and
eosinophil recruitment to the lungs in the murine
asthma model [19]. Besides, using the same model, we
have also observed that antigen-induced mast cell degra-
nulation is somehow impaired [20]. It is worthy to men-
tion that these cells are very involved in acute asthma
attacks [21,22]. In this 5 context, it has been demon-
strated that estradiol also facilitates histamine release
after antigen challenge [23], where estradiol a-receptor
seems to play a role using a non-genomic pathway [24].
Besides, estradiol upregulates cellular recruitment and
cytokine release into lungs after antigen challenge in
rats [20,25].
Using a rat model of allergic lung inflammation, we
have also demonstrated that antigen sensitization 7 days
after ovaries removal culminates in a drastically
decreased cell recruitment into lungs after antigen
challenge [25]. Similarly, allergic response triggered in
intact females upon tamoxifen treatment was found also
reduced [26]. Tamoxifen has a triphenylethylene struc-
ture (C26H29NO) wich directly blocks the effect of estro-
gen on tissue, preventing estrogens from binding and
activating the cell [27]. Thus, as tamoxifen is a well-
recognized estradiol receptor modulator these data
reinforce the involvement of sex hormones, notably
estradiol, over the immune allergic response. Overall, we
[20,25,19] and others [28] have observed that estradiol
displays pro-inflammatory actions, such as the already
mentioned mast cell degranulation and bronchial hyper-
responsiveness. On the other hand, estradiol is also
reported to improve lung function during perimenstrual
asthma [29], ameliorating lung inflammation and
decreasing lung remodeling in murine asthma model
[30]. Taking these evidences into account, it is notice-
able the conflicting picture regarding the effects of sex
hormones on asthma [31,27]. Thus, the situation
deserves a better understanding on the role of sex hor-
mones in inflammatory mechanisms underlying lung
inflammation.
In the present study, we hypothesize that the profile of
circulating sex hormones during antigen sensitization
exerts a pivotal role on the scores of allergic lung
inflammation. To examine that we investigated the mag-
nitude of allergic lung inflammation and the release of
inflammatory mediators in female rats sensitized to anti-
gen 1 day after ovariectomy.
Materials and methods
Animals
Female Wistar rats (180-220 g) from the Institute of
Biomedical Sciences animal facilities were used through-
out. Animals were housed in groups of five rats per cage
in a light- and temperature-controlled room (12/12-h
light-dark cycle, 21 ± 2°C) with free access to food and
water. All experiments were approved by the local Ani-
mal Care Committee.
Ovariectomy (OVx)
Rats were anesthetized with an intraperitoneal injection
of ketamine-xylazine (100 and 20 mg/kg, respectively).
Upon laparotomy the ovaries were removed free from
adherent tissue. The surgical wound was sutured and
animals received a single dose of Pentantibiotic® (570
mg/kg) by intramuscular route. Vaginal smears, quantifi-
cation of the uterine weight and determination of the
circulating levels of estradiol and progesterone, were
used in order to assess the effectiveness of OVx. Simi-
larly operated rats except for ovaries removal were used
as the sham-operated controls (Sham-OVx group).
A non-manipulated group of female rats (Basal group)
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was used to obtain the normal basal values of all para-
meters studied.
Sensitization and antigen challenge
One day after ovaries removal, (OVx) or Sham-OVx rats
were sensitized by an intraperitoneal injection of a sus-
pension of 10 μg of OVA with 10 mg aluminum hydro-
xide. One week later, rats were boosted subcutaneously
with 10 μg of OVA dissolved in phosphate buffer solu-
tion (PBS). Two weeks after first sensitization, rats were
subjected to a single 15-min exposure of aerosolized
OVA (1% in PBS) using an ultrasonic nebulizer device
(Icel, São Paulo, Brazil) coupled to a plastic inhalation 7
chamber (18.5 × 18.5 × 13.5 cm) and labeled as “aller-
gic”. Rats were euthanized 24 h after challenge by sec-
tioning of the abdominal aorta under deep chloral
hydrate anesthesia (> 400 mg/kg ip) (Fig. 1).
Bronchoalveolar lavage (BAL) and cell countings
A total volume of 40 ml (twice, 20 ml) of PBS was
injected into the rat lungs by tracheal route [25]. BAL
fluid was collected and centrifuged (170 g, 10 min) and
the cell pellet resuspended in 1 ml PBS. Aliquots of cell
suspension (90 μl) were stained with 10 μl of 0.2% crys-
tal violet and total cells quantified by microscopy using
Neubauer chamber. Differential cell countings (neutro-
phils, eosinophils, and mononuclear cells) were carried
out using standard morphological methods after cytos-
pin processing and Rosenfeld’s dye staining.
Blood leukocytes and bone marrow cell counts
Peripheral blood leukocytes and bone marrow cells were
quantified in samples from the tail vein and from ali-
quots of medullary femural lavage (FL) respectively [20].
Blood aliquots were diluted (1:20) in Türk fluid (3%
acetic acid) and cells of FL were resuspended in PBS (1
ml), stained with crystal violet (0.2%). The quantitative
analyses of cells were performed in blood smears and
FL samples stained with Rosenfeld’s dye [20]
Determination of TNF-a, IL-10, LTB4 and nitrites levels
Total cells recovered from BAL were suspended in 10%
fetal bovine serum (FBS)-enriched, RPMI-1640 culture
medium (1000 μL). The trypan blue exclusion test was
employed to determine cell viability. Aliquots (500 μl)
containing 2 × 106 cells/ml were platted into 24-well
plastic microplates under a 5% CO2-95% O2 atmosphere
at 37°C. Aliquots of supernatants were collected 24 h
later and stored at -80°C. TNF-a activity was evaluated
by a cytotoxicity assay using L-929 cells as described
previously [32]. TNF-a titer (U/ml) is defined as the
reciprocal of the dilution that induces 50% of lysis of
L-929 cells. LTB4 and IL-10 concentration were quanti-
fied in samples of BAL and FL cells using ELISA kits
purchased from R&D Systems (Minneapolis, MN).
Detection limit was 7.8-500 pg/ml for LTB4 and 62.5-
4000 pg/ml for IL-10. Nitrites concentration was deter-
mined by colorimetric assay (540 nm) in supernatant of
cellular cultures of total BAL and the FL using the
Griess reaction [33]. In brief, 2.0 × 106 cells/ml BAL or
the FL were distributed in plastic microplates of 24
wells containing RPMI-1640 culture medium (1 ml)
supplemented with 10% FBS. The reaction was per-
formed adding 50 μl of BAL or FL cells culture superna-
tant in plastic microplates (96 wells) containing the
equal volume of Griess reagent at room temperature for
10 min. Aliquots of supernatants of BAL or FL cultured
cells from non-manipulated rats (Basal group) were
used as controls. The optical density was obtained using
automatic ELISA reader (Bio-Tek Instruments®), and the
concentration of nitrites were determined using pre-
viously established standard curve of NaNO2 (5-60 μM).
Estradiol and progesterone quantification
Blood samples were collected from the orbital plexus of
anesthetized rats before immunization (day 0, corre-
sponding to 1-day OVx), at the booster (day 7, corre-
sponding to 8-day OVx), at the challenge (day 14,
corresponding to 15-day OVx), and 24 h after antigen
challenge (day 15, corresponding to 16-day OVx). Ali-
quots of blood were centrifuged (170 g, 10 min), and
the resulting sera were stored at -70°C until further ana-
lyze. The hormones were determined using ELISA kits
(Diagnostic Products, Los Angeles, CA). Detection limits
were 0.011-0.025 pg/ml for estradiol and 0.009-0.020
ng/ml for progesterone.
Immunohystochemistry for lung E-Selectin expression
Animals were euthanized as described, lungs exposed
and filled by the trachea with 10 ml of tissue freezing
medium (OCT - Leica Instruments, Wetzlar, Germany)
dilute 1:3 in distilled water. Trachea and lungs were
then removed and small fragments immersed in hexane
in liquid nitrogen. Samples were submitted to 8 μm
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Figure 1 Experimental design of ovariectomy (OVx) and
ovalbumin-(OVA) sensitization. Anesthetized rats were subjected
to ovariectomy (OVx) and at the indicated day 1 were ovalbumin
(OVA) sensitized. Control group consisted of rats submitted to
similar manipulations excepting the ovaries removal (Sham-OVx).
Sensitized rats were boosted with OVA (Day 8), and the OVA-
challenge performed at day 15. The rats were euthanized at day 16
(see material and methods for more details).
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sections and fixed in acetone for 10 min. All sections
were washed 3 times in PBS during 30 min and then kept
in hydrogen peroxide (3%) for 10 min at room tempera-
ture for endogenous peroxidase activity blocking. Slides
were washed again 3 times in PBS and then blocked for
unspecific binding with BSA (10% - 30 min) and Super
block solution (Thermo Scientific Pierce Protein
Research Products, Rockford, USA) for 2 h at room tem-
perature in chambers with controlled humidity. After-
wards, all slides were incubated with anti-E-selectin at
1:50 in PBS/Tween 20 (0.3%, 4°C overnight). Following
incubation, samples were washed in PBS and incubated
with biotinilated secundary antibody mouse anti-Rat IgG
(1:1000) for 1 h at room temperature. After that, slides
were washed in PBS and incubated with streptavidin-
peroxidase (Vectastain ABC Kit - Vector Laboratories,
CA, USA) for 1 h at room temperature. Assay was then
performed with 0.5 mg/ml of diaminobenzidine (DAB -
BioGenex, CA, USA) and hydrogen peroxyde 0.06% for
visualization. Samples were counter-stained with hema-
toxilin eosin and submitted to dehydration with ethanol
(70% - 90% -95% - 100%), diafanization (Xylol - Merck,
Sao Paulo, Brazil) and then covered with Entellan
(Merck, Sao Paulo, Brazil) and coverslip. All analyses
were performed comparing at least 3 samples from the
same animal for a total of 3 animals per group. Bronchial
regions were selected and the antibody stained regions
were determined by imaging software analysis KS-300
(Carl Zeiss, Jena, Germany). Results are expressed as
staining density at arbitrary units.
Pharmacological treatments
Twenty-four hours prior to OVA challenge, groups of
OVx allergic rats were treated with a single subcuta-
neous injection of 17b-estradiol (280 μg) or progester-
one (200 μg). Controls consisted of OVx allergic rats
subjected to injection with the corresponding volumes
of the hormone vehicles (corn oil for 17b-estradiol or
distilled water for progesterone).
Statistical analysis
Data are presented as mean ± S.E.M. Comparisons
between groups were made by one-way ANOVA fol-
lowed by Newman-Keuls post test. The 4.0 version of
GraphPad InStat Software was used for these purposes.
Values of P < 0.05 were considered significant.
Results
Circulating levels of estradiol and progesterone at
the phases of OVA-immune sensitization
Table 1 shows that at the day of OVA-sensitization,
serum levels of estradiol and progesterone of 1-day OVx
rats were similar to those found in estrous. At the boos-
ter day (8-day OVx), the serum levels of estradiol and
progesterone drastically reduced comparatively to those
found at the OVA-sensitizing day. At the challenge (15-
day OVx) and at the experiment day (16-day OVx), the
concentration of estradiol and progesterone did not dif-
fer from those found at the booster day (8-day OVx). In
a parallel set of experiments, we observed that vaginal
smears of OVx rats were morphologically compatible
with diestrous phase. In addition, the uterus weight of
OVx rats significantly reduced compared with that of
Sham-OVx rats (data not shown).
Repercussion of ovaries removal (OVx) to OVA-induced
allergic lung inflammation
As demonstrated in Fig 2, ovaries removal 1 day prior to
OVA-sensitization was associated with an increased
number of cells collected in BAL (OVx allergic) when
compared with the cells collected in BAL of Sham-OVx
allergic rats. Moreover, the number of mononuclear
cells, neutrophils (Fig 2A) as well as eosinophils (Fig
2B), was significantly increased in both groups of aller-
gic rats (Sham-OVx and OVx) but such increase was
more pronounced in OVx allergic rats.
Changes in blood leukocytes and bone marrow
cells counting in OVx-allergic rats
Once we observed a significant increase in cell count-
ings in BALs from OVx allergic rats, we sought to eval-
uate whether OVx might modify the circulating cell
profile in blood and bone marrow. Fig. 3 shows that
allergic Sham-OVx and OVx allergic rats had increased
countings of circulating leukocytes (Fig. 3A) whereas the
reduced number of bone marrow cells were not affected
by ovaries removal (Fig. 3B). Interestingly, OVx allergic
rats reduced the blood leukocytes counting and
increased that of bone marrow cells comparatively to
those found in the Sham-OVx allergic group.
Table 1 Serum levels of estradiol and progesterone
before and after OVx and the effects of treatments with
estradiol or progesterone before albumin challenge
Estradiol
(pg/ml)
Progesterone
(ng/ml)
Sham OVx Estrous 15.6 ± 3.0 10.6 ± 1.2
Diestrus 8.3 ± 1.5 21.3 ± 1.2
Metaestrus 15.2 ± 1.0 21.0 ± 0.2
Proestrus 34.3 ± 4.6 4.0 ± 0.2
OVx At sensitization (1-day OVx) 11.4 ± 1.5 13.8 ± 3.0
At booster (8-day OVx) 5.9 ± 0.3 4.8 ± 1.0
At challenge (15-day OVx) 5.7 ± 1.8 3.9 ± 0.3
At experiment (16-day OVx) 5.2 ± 1.5 3.2 ± 0.3
Values are means ± SE of radioimmunoassay data from 5 rats/group. Orbital
plexus blood as taken under deep anesthesia from sham OVx allergic and
Sham-Ovx allergic rats at various time points corresponding to the
experimental steps.
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Effects of estradiol and progesterone treatments
BAL cells count
As shown in Fig 4A, estradiol treatment of rats pre-
viously to OVA-challenge prevented the increased cell
counting of BAL collected from OVx allergic rats as
compared to non-treated OVx allergic rats. In addition,
an intense reduction of eosinophil counting in BAL of
OVx allergic rats was also found after estradiol treat-
ment (Fig. 4B). On the other hand, progesterone treat-
ment of rats did not modify the augmented number of
cell counting of BAL of OVx allergic rats caused by
OVA-challenge.
Blood leukocytes and bone marrow cells count
Fig 5A shows that estradiol, but not progesterone, treat-
ment of OVx allergic rats prevented the decreased blood
cell counting as found in blood of non-treated OVx
allergic rats. In contrast, estradiol and progesterone
treatments did not alter the bone marrow cells counting
(Fig 5B).
Tumor necrosis factor-a (TNF-a) and interleukin 10 (IL-10)
release by cultured cells
TNF-a is a proinflammatory cytokine which has been
implicated in many aspects of the airway pathology in
asthma. It directly induces histamine release from mast
cells and also potentiates its cytokine secretion. More-
over, TNF-a is particularly important in the develop-
ment of airway hyperresponsiveness [34]. Our data
revealed that TNF-a levels released by BAL-cultured
cells of Sham-OVx and OVx allergic rats were signifi-
cantly higher than those found in BAL cells of the Basal
group. After progesterone treatment of OVx allergic
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Figure 2 Total mononuclear cells and neutrophils (A) and eosinophil counts (B) in bronchoalveolar lavage (BAL) fluid of allergic rats
(Sham-OVx and OVx). Basal values were obtained from nonmanipulated rats. Data are means ± SE from 5-8 experiments. *P < 0.05 compared
with the basal group; j P < 0.05 compared with the Sham-OVx allergic group.
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rats, TNF-a levels generated by BAL cultured cells were
significantly increased as compared to their untreated
counterparts, whereas estradiol treatment did not
change the TNF-a secretion by BAL cells (Fig. 6A).
Bone marrow cells (Fig. 6B) from estradiol-treated OVx
allergic rats significantly decreased the concentration of
TNF-a regarding the cells from untreated OVx allergic
rats, while progesterone treatment did not change the
TNF-a generation.
IL-10 is anti-inflammatory cytokine exerting it effects
as potent inhibitor of monocyte/macrophage function
and the production of pro-inflammatory cytokines [35].
In this context, we sought to evaluate the IL-10 pro-
duced by BAL-cultured cells from Sham-OVx and OVx
allergic rats. Our data showed that the level of this cyto-
kine did not differ between the Sham -OVx and OVx
rats. On the other hand, estradiol treatment of OVx-rats
markedly increased the generation of IL-10 whereas
progesterone was ineffective to alter such levels (Fig.
7A). Regarding bone marrow cells, estradiol and proges-
terone treatments of rats significantly decreased the
levels of IL-10 of OVx allergic as compared to untreated
OVx allergic rats. By contrast, irrespective of ovaries
removal, IL-10 levels generated by bone marrow cells
were similar among the groups (Fig 7B).
Leukotriene B4 (LTB4) and nitrites production by cultured
cells
Leukotrienes are widely known for their properties as
potent bronchoconstrictors, ability to increase airway
responsiveness, vascular permeability and mucus pro-
duction [36]. Its activities include chemotaxis of neutro-
phils and eosinophils, aggregation of neutrophils, and
enhanced expression of complement receptors on gran-
ulocytes. Similarly, nitric oxide is also thought to be
involved in asthma, including tissue repair, vasodilation
and inflammation as extensively reviewed [36,37]. Due
to these features, we also decided to quantify LTB4 and
nitrites levels in samples of BAL-cultured cells. Cells of
OVx allergic rats released higher amounts of LTB4, an
effect which was significantly prevented by estradiol or
progesterone treatments before OVA- challenge (Fig.
8A). In contrast, bone marrow cells from Sham OVx
allergic rats significantly increased LTB4 levels compared
to bone marrow cells of basal group. Although OVx did
not modify LTB4 release by bone marrow cells, estradiol
treatment of rats decreased the LTB4 quantification
whereas progesterone was ineffective (Fig. 8B).
OVx increased the concentration of nitrites released
by cultured-BAL cells after OVA-challenge (OVx-aller-
gic) but such levels were not affected by estradiol treat-
ment. On the other hand, progesterone treatment
effectively decreased the nitrites release caused by OVA-
challenge (Fig. 9A). Nitrites levels released by bone mar-
row cells were significantly increased by OVx in allergic
rats and were reduced by estradiol and progesterone
treatments (Fig. 9B).
Regulatory role of sex hormones on the lung expression
of E-selectin in allergic rats
Ovaries removal significantly increased E- selectin
expression in lungs of allergic rats when compared to
lungs of Sham OVx- allergic rats. Lungs of OVx-allergic
rats upon estradiol treatment decreased the E-selectin
expression to levels close to those found in lung of
Sham-OVx allergic rats. In contrast, progesterone treat-
ment did not exert effects on the E-selectin expression
of lung of OVX-allergic rats (Fig. 10A). Representative
pictures of immunohistochemical lung expression of E-
selectine in OVx allergic rats and their matched controls
are depicted in Fig. 10B.
Basal Sham-OVx OVx
0
5000
10000
15000
20000
A
*
φ
Allergic
Le
uk
oc
yt
es
 (m
m
3 )
Basal Sham-OVx OVx
0
100
200
300
400
500
B
*
φ
Allergic
To
ta
l o
f c
el
ls
 (x
 1
0
6 )
Figure 3 Number of cells in peripheral blood (A) and in bone
marrow (B) from allergic Sham-OVx and OVx rats. Basal values
were obtained from nonmanipulated rats. Data are means ± SE
from 5-8 experiments. *P < 0.05 compared with the basal group; j
P < 0.05 compared with the Sham-OVx allergic group.
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Discussion
The scope of this study holds on to the fact that women
at the perimenstrual period and those at postmenopause
upon hormonal replacement therapy show worsened
asthma symptoms. On the other hand, asthmatic fertile
women under oral contraceptive usage display reduced
Th2 responses, reduction in asthma symptoms,
improvement of lung function, and/or reduction in
medication use in women taking hormonal preparations
[9,11,12,14]. Overall, it is clear that the outcome of the
allergic response differs whether under oscilating or
decreased levels of female sex hormones. These evi-
dences highlight a causal link between the oscillations of
sex hormones and the overall allergic response. How-
ever, the role of the fluctuations of sex hormones on the
inflammatory aspects of allergic lung disease is yet
unclear.
Here, using a well-established rodent model of allergic
lung disease we have reported the contrast between the
lung inflammatory response of ovariectomized (OVx)
allergic rats compared to found in Sham-OVx allergic
animals. We observed that rats upon ovaries removal 1
day prior to OVA-sensitization when subjected to OVA-
challenge developed a more robust increase of eosino-
phils, neutrophils and monocytes cells into lung. In
addition, an increased E-selectin expression in lungs was
also found. In the context of cell trafficking, caused by
allergic challenge, the ovaries removal increased the
number of bone marrow cells and decreased that of per-
ipheral blood leukocytes. Altogether, these events might
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Figure 4 Involvment of estradiol and progesterone in total cells, mononuclear cells and neutrophils (A) and eosinophils (B) recovered
in BAL of rats subjected to allergic lung inflammation. Estradiol (280 μg s.c., single dose) and progesterone (200 μg s.c., single dose)
replacement was performed in OVx rats 24 h before the antigen challenge. Data are means ± SE from 5-8 experiments. j P < 0.05 compared
with the Sham-OVx allergic group; Δ P < 0.05 compared to the OVx group.
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justify the accumulation of inflammatory cells into lung
after OVA challenge in OVx rats.
As the ovaries removal of rats was carried out pre-
viously to OVA-immune sensitization then these data
allowed us to recognize, as reported earlier [38], a puta-
tive role of female sex hormones on the mechanisms
involving the adaptative immunity response and
immune system cells, notably on those of allergic lung
inflammation. An important point of our model of aller-
gic lung inflammation is that the OVA-immunization
was performed 1 day after the ovaries removal, whereas
the allergic immune response (OVA challenge) was trig-
gered two weeks later. Therefore, the decreasing of cir-
culating levels of estradiol and progesterone after
ovaries removal occurred during the OVA-immune
sensitization process. As the percentage of bronchial
mast cells degranulation of OVx allergic rats after OVA
challenge was similar to observed in sham OVx allergic
rats and keeping in mind that IgE exerts a crucial role
on the immune mechanisms involvingimmune mast cell
degranulation, we concluded that synthesis of anafilatic
antibodies was not affected by ovaries removal. We
observed that cells collected of BAL and of bone mar-
row of OVx allergic rats significantly increased the
release of inflammatory mediators such as LTB4, NO
and TNF-a. Thus, female sex hormones not only
mediated the cell influx but also modulated the func-
tional activity of phagocytes recruited by the allergic
challenge.
As the two major ovarian hormones are estradiol and
progesterone and ovariectomy augmented the number
of inflammatory cells into lung after the allergic
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means ± SE from 5-8 experiments. j P < 0.05 compared with the
Sham-OVx allergic group; Δ P < 0.05 compared to the OVx group.
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Figure 6 TNF-alpha released by BAL (A) and bone marrow cells
(B) 24 h after in vivo antigen challenge of allergic rats (Sham-
OVx and OVx). Rats of OVx allergic groups were treated with
estradiol or progesterone before the antigen challenge. Basal values
were obtained from nonmanipulated rats. Data are means ± SE
from 5-8 experiments. *P < 0.05 compared with the basal group; j
P < 0.05 compared with the Sham-OVx group; Δ P < 0.05 compared
with the untreated OVx allergic group.
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challenge, then we treated OVx rats with estradiol or
progesterone previously to OVA challenge. Our data
showed that estradiol but not progesterone prevented
the excessive cell infiltration into the lung and also rees-
tablished the number of blood circulating leukocytes at
the levels of sham OVx allergic rats. Estradiol exerts its
effects acting on inflammatory cells bearing a and b
receptors [39]. In the present study estradiol was admi-
nistered to OVx rats 24 h before the OVA-challenge, a
fact that preclude any speculation regarding its genomic
and non genomics effects on lung inflammation control.
On the other hand, estradiol could be considered as
endogenous regulator of mechanisms associated to cell
adhesion and consequently might interfere with func-
tional activity of leukocytes. Indeed, E-selectin expres-
sion of lung was decreased in estradiol treated OVx
allergic rats. Considering the involvement of E-selectin
on the leukocyte accumulation at the inflammatory site
[40], then the magnitude of allergic lung inflammatory
is endogenously controlled by estradiol. Interestingly,
estradiol prevents artery wall thickness by mechanism
involving a diminished E-selectin expression in postme-
nopausal women [41]. Thus, our data reveal that during
the allergic lung inflammation, estradiol downregulated
the cell recruitment likely preventing the cell adhesion.
As estradiol exerts a protective role of endothelium we
hypothesized that it could be a therapeutic tool for aller-
gic lung diseases as developed in this study. Indeed,
experimental evidences suggest that estradiol prevent
the lung inflammatory aspects of asthma. Moreover, in a
non allergic model estradiol protects the lung from
inflammation caused by innate immune response such
as induced by hemorrhagic shock and endotoxin [42].
Next, we investigated the interaction of sex hormones
on functional activity of phagocytes measuring the levels
of inflammatory mediators in supernatants of BAL and
bone marrow cultured cells from OVx allergic rats. Our
data indicated that TNF-a generation in lung cells was
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Figure 7 IL-10 released by BAL (A) and bone marrow cells (B)
24 h after in vivo antigen challenge of allergic rats (Sham-OVx
and OVx). Rats of OVx allergic groups were treated with estradiol or
progesterone before the antigen challenge. Basal values were
obtained from nonmanipulated rats. Data are means ± SE from 5-8
experiments. *P < 0.05 compared with the basal group; j P < 0.05
compared with the Sham-OVx group; Δ P < 0.05 compared with the
untreated OVx allergic group.
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Figure 8 LTB4 released by BAL (A) and bone marrow cells (B)
24 h after in vivo antigen challenge of allergic rats (Sham-OVx
and OVx). Rats of OVx allergic groups were treated with estradiol or
progesterone before the antigen challenge. Basal values were
obtained from nonmanipulated rats. Data are means ± SE from 5-8
experiments. *P < 0.05 compared with the basal group; j P < 0.05
compared with the Sham-OVx group; Δ P < 0.05 compared with the
untreated OVx allergic group.
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up regulated by progesterone while estradiol prevented
the release of this cytokine by the bone marrow cells.
Interestingly, there are studies indicating that ovariect-
omy reduces serum levels of TNF-a [43]. Nevertheless,
our study was carried out using ovariectomized allergic
rather than naïve animals. In this context TNF-a
increase shown by our data is thus considered a phe-
nomenon that is secondary to antigen sensitization and
challenge. In addition, IL-10 levels increased in lung
cells of OVx allergic rats upon estradiol treatment.
Speculatively we infer that a high level of IL-10 was
associated to TNF generation in order to opposite the
inflammatory effects of TNF on lung inflammation. In
parallel, LTB4 release by lung cells was prevented by
estradiol and progesterone. Along with TNF-a and
LTB4 which share pro-inflammatory activity [44] and
NO exerts pro and antinflammatory effects [45], our
data revealed that sex hormones interfered with NO
generation by cultured cells. We found that the high
levels of nitrites in cultured cells of OVx allergic rats
were a progesterone-mediated event. However, it is yet
unclear how NO generated in the lung environment
could decrease the leukocyte endothelium interaction.
In this context, as progesterone treatment decreased
NO generation, its effects could account for the worsen-
ing of the allergic lung inflammation. In fact, decreasing
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Figure 9 Nitrites released by BAL (A) and bone marrow cells
(B) 24 h after in vivo antigen challenge of allergic rats (Sham-
OVx and OVx). Rats of OVx allergic groups were treated with
estradiol or progesterone before the antigen challenge. Basal values
were obtained from nonmanipulated rats. Data are means ± SE
from 5-8 experiments. *P < 0.05 compared with the basal group; j
P < 0.05 compared with the Sham-OVx group; Δ P < 0.05 compared
with the untreated OVx allergic group.
Figure 10 Immunohystochemistry for lung E-Selectin
expression of cells from BAL of allergic rats (Sham-OVx and
OVx). Rats of OVx allergic groups were treated with estradiol or
progesterone before the antigen challenge. Basal values were
obtained from nonmanipulated rats. Data are means ± SE from 5-8
experiments. *P < 0.05 compared with the basal group; j P < 0.05
compared with the Sham-OVx group; Δ P < 0.05 compared with the
untreated OVx allergic group.
de Oliveira et al. Respiratory Research 2010, 11:115
http://respiratory-research.com/content/11/1/115
Page 10 of 12
NO, progesterone effects could increase cell adhesion
and recruitment. On the other hand, estradiol increasing
IL-10 levels and decreasing those of TNF-a and LTB4
could prevent cell mobilization into lung after OVA-
challenge. Noteworthy, estradiol protects airways of
experimental hyperresponsiveness since it increases air-
ways AChE activity as well as prevents mucus and col-
lagen deposition in asthma models [46,30].
Our data also showed that progesterone did not mod-
ify the cell influx into the lung of OVx allergic rats, but
was effective to increase the levels of TNF-a, and
decrease those of LTB4 and NO released by BAL-cul-
tured cells. Analyzing the profile of inflammatory media-
tors released by recruited cells, estradiol effects might be
considered as a lung inflammatory deterrent while pro-
gesterone could be interpreted as a lung inflammation
accelerator. Interestingly, despite the mobilization of
bone marrow cells towards to inflammatory site repre-
sents a relevant step of defensive response against a
noxious stimulus [47] our data revealed that sex hor-
mones are not the regulators of bone marrow cell
traffick.
It is worthy to mention that the marked allergic lung
inflammation observed here was found in OVA sensi-
tized rats 1 day after ovaries resection (OVx-1 protocol).
On the other hand, previously, we demonstrated that
rats OVA-sensitized 7 days after OVx (OVx-7 protocol)
when exposed to OVA challenge markedly blunted the
cell influx into lung [25], which was reverted by estra-
diol treatment. Thus, in contrast to data utilizing OVx-7
protocol [19,20], in the present study (OVx-1 protocol)
estradiol clearly showed a protective role in allergic lung
inflammation. The profile of circulating sex hormones
at the time of OVA sensitization and those at the time
of OVA challenge could justify the polarized effects of
sex hormones on the allergic lung inflammation among
OVx-1 and OVx-7 protocols. Indeed in OVx-1 protocol
circulating levels of estradiol and progesterone, at the
time of OVA-sensitization and challenge, were compati-
ble with estrous and diestrous phases respectively (Table
1). On the other hand, in the OVx-7 protocol the OVA-
sensitization and challenge were performed at diestrous
phase [20]. Thus, we suggest that estradiol and proges-
terone levels at the period of the first contact of the
organism with the antigen could determine the pheno-
type of allergic lung inflammation. As estrogen inhibits
the 11b-hydroxysteroid dehydrogenase type I isoenzyme
activity, reducing the anti-inflammatory effects of corti-
sol [48], we infer that at low levels of estradiol an
intense allergic lung inflammation might be triggered, as
observed in OVx-1 protocol. Thus, consistent with the
literature, fluctuations of sex hormones during men-
strual cycle modifies leukocyte immune function [35],
leading to impairment of the inflammatory response
during the allergic lung inflammation [15,29]. Our data
point out to the relevance of sex hormones status of
women (estradiol/progesterone) at the time of sensitiza-
tion/antigen challenge.
Conclusions
The clinical implication of this study relies on estradiol
and progesterone as modulators of the phenotype of an
allergic lung inflammation. Our data contribute to the
understanding of mechanisms underlying the deteriora-
tion of asthma symptoms in women, clinically observed
during and after the fertile phase of the female repro-
ductive cycle.
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